- Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM dealAnother $200M for Mentari: Migraine drug developer Mentari Therapeutics has lined up a second private placement as it works to close its reverse merger with InMed Pharmaceuticals. The Paragon Thera…Endpoints · 2d ago↗ source
- Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's preventionLONDON — Eli Lilly, the world’s biggest drugmaker, appears to be getting more ambitious about tackling brain diseases. Last week, the company announced it would pay $2.8 billion upfront to acquir…Endpoints · 2d ago↗ source
- STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and morePresident Trump plans to impose tariffs on imported generic medicines, his latest threat aimed at bringing pharmaceutical manufacturing back to the U.S.